InverseOne

Home

Sam Chun Dang Pharm

000250, KOSDAQ, Healthcare

₩163,500▲ ₩7,399+4.74%
Prev. close
₩156,101
Volume
59K
Market cap
₩3.8T
  • Market leader
  • Near 52-week low
  • -87% from high

Stock and sector context

Healthcareinflow
Sector comparison
Of 13 covered Healthcare stocks in Korean, 8 rose; the average change was +0.59%. Sam Chun Dang Pharm had the largest rise at +4.74%. Estimated sector flow was inflow.
Variables to watch
Drug approvals and trial resultsDrug pricing policyUS interest ratesUSD/KRW
Risks to check
  • -87% below the high, the downtrend may continue
  • Clinical trial failure
  • Drug pricing pressure

This compares price changes among covered stocks in the same market. It does not establish why prices moved. Variables and risks are sector reference lists.

Why a candidate

Exp 83/100

The 0–100 score combines the 52-week range, valuation metrics, price changes and volume. It is not a probability of rising or a forecast return.

Gap to 52w high +654%OversoldInflowMomentum +4.7%

Today's read

Sam Chun Dang Pharm scores 83 out of 100 on today's InverseOne expectation ranking, 1 of 60 in the Korean large-cap universe. There is 654% of room left to its 52-week high. Today's move of +4.74% came with money flowing in, alongside the Healthcare sector. Scores are estimates built from price and volume, a starting point for research rather than a trading signal.

Data basis: 2026-09-17 close, 09-19 00:18 KST updated, For reference only, not advice

Lending balance

Unwinding

1,355,214 sh

KRW 0.22T

1D -1.28%5D +1.77%

New 2,395 sh, Returned 20,008 sh

Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.

As of 2026-09-17, FSC stock lending data

Talk about this stock

New thread

Today's talking points

  • It sits low in its 52-week range (4).
  • Borrowed shares are coming back. The lending balance is shrinking.
  • It is 654% below its 52-week high.

Three months out, which way do you see it?

Nobody has answered yet. Sign in to be the first.

These are answers picked by members, not investment advice.

Fund-flow signal

Unlock this stock's fund-flow signal and multi-day trend

  • Estimated net flow and signal grade, based on price and volume
  • Money-flow rank within the market and sector
  • 7-day flow trend and streak
  • Overlapping combo readings
Today's data for this stock is ready

Name, deep signal, 7-day trend, trade

1 credit. Reopening the same stock costs nothing.

Market data

52-week range
₩120,000 ~ ₩1,233,000
52-week position4/100
₩120,000₩1,233,000
Upside to 52w high+654.1%

AI zone read

Related news

From the headlinesBad news

Same-sector stocks

Celltrion068270, Healthcare+1.75%CLASSYS214150, Healthcare-1.72%ST Pharm237690, Healthcare+1.66%Lunit328130, Healthcare+1.10%Celltrion Pharm068760, Healthcare+1.03%Samsung Biologics207940, Healthcare-0.92%LigaChem Biosciences141080, Healthcare+0.73%ALTEOGEN196170, Healthcare-0.59%

These figures are reference estimates built from price and volume: a starting point for narrowing down ideas, not a buy or sell signal.